Phase I: Disparities in Access to Advanced Medical Procedures in the Medicare Population

Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.

AdvaMed is dedicated to ensuring our industry focuses their efforts on treating and raising the awareness of women’s health conditions.

The final report of a three-part series investigates the prevalence of racial and ethnic disparities in the use of in the use of advanced interventions in the Medicare program.

The second of a three-phase research series examines the difference in access to certain advanced interventions, including a range of surgical, medical and technological interventions.

This February, AdvaMed is working with member companies and our global partners to raise awareness and highlight the ways medical technology helps those living with cardiovascular disease live healthier, happier lives.

MIDI describes recent advancements their team engineered in the biopharma fabrication space.

AdvaMed, the medtech association, today released the following statements on the White House’s announcement today of a new initiative focused on women’s health research to be led by First Lady Jill Biden. This year, AdvaMed created a Board-level committee to address health disparities more broadly, led by AdvaMed Board of Directors member Lishan Aklog, M.D., as well as a Board-level subcommittee on women’s health, led by AdvaMed Board member Tracy MacNeal. Statements from both medtech leaders follow.

We are committed to ensuring that our mission is not compromised by the perpetuation of racial health disparities.